Henry Schein Inc Revenue Growth Rates (HSIC), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Henry Schein Inc   (NASDAQ: HSIC)
 

HSIC's Revenue Growth by Quarter and Year

Henry Schein Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/HSIC/growth
https://api.csimarket.com/api/v1/companies/HSIC/fundamentals
https://api.csimarket.com/api/v1/companies/HSIC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
HSIC Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3,471.00
2nd Quarter June 3,458.00
1st Quarter March 3,368.00
FY 10,297.00

HSICs Annual Revenue
Henry Schein Inc 's Revenue in the fiscal year 2025 $ 13,184.00 millions
Henry Schein Inc 's Revenue in the fiscal year 2024 $ 12,673.00 millions
Henry Schein Inc 's Revenue in the fiscal year 2023 $ 12,339.00 millions
Henry Schein Inc 's Revenue in the fiscal year 2022 $ 12,647.00 millions
Henry Schein Inc 's Revenue in the fiscal year 2021 $ 12,401.02 millions




HSIC Revenue third quarter 2026 Y/Y Growth Comment
Henry Schein Inc reported Revenue growth of 3.95% year on year in the third quarter 2026, to $ 3,471.00 millions, this is lower than Henry Schein Inc 's recent average Revenue growth of 5.37%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 119 other companies have achieved higher Revenue growth. While Henry Schein Inc ' s Revenue increase of 3.95% ranks overall at the positon no. 2427 in the third quarter 2026.


HSIC Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.95 %
2nd Quarter June 6.73 %
1st Quarter March 6.31 %
FY   -

Financial Statements
Henry Schein Inc 's third quarter 2026 Revenue $ 3,471.00 millions HSIC's Income Statement
Henry Schein Inc 's third quarter 2025 Revenue $ 3,339.00 millions Quarterly HSIC's Income Statement


HSIC Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 0.38 %
2nd Quarter June 2.67 %
1st Quarter March -2.01 %
FY (Year on Year)   -


Back to HSIC Growth rate Comparisons >> Back to HSIC Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #344
Overall #2427

Revenue Y/Y Growth Statistics
High Average Low
76.16 % 5.37 % -31.19 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #120
Healthcare Sector #344
Overall #2427
Revenue Y/Y Growth Statistics
High Average Low
76.16 % 5.37 % -31.19 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Henry Schein Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
68.61 % 1.75 % -30.65 %
(Sep 26 2020)  


HSIC's III. Quarter Q/Q Revenue Comment
Henry Schein Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.38% quarter on quarter, to $ 3,471.00 millions.

Within Medical Equipment & Supplies industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Henry Schein Inc 's Revenue growth quarter on quarter, overall rank is 1754.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #73
Healthcare Sector #230
Overall #1754
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #73
Healthcare Sector #230
Overall #1754
Revenue Q/Q Growth Statistics
High Average Low
68.61 % 1.75 % -30.65 %
(Sep 26 2020)  


HSIC's III. Quarter Q/Q Revenue Comment
Henry Schein Inc achieved in the III. Quarter 2026 below company average Revenue growth of 0.38% quarter on quarter, to $ 3,471.00 millions.

Within Medical Equipment & Supplies industry 72 other companies have achieved higher Revenue quarter on quarter growth. While Henry Schein Inc 's Revenue growth quarter on quarter, overall rank is 1754.


Henry Schein Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 26 2026)		 12 Months Ending (Jun 27 2026) 12 Months Ending (Mar 28 2026) 12 Months Ending (Dec 27 2025) 12 Months Ending (Sep 27 2025)
Cumulative Revenue 12 Months Ending $ 13,734.00
Y / Y Revenue Growth (TTM) 6.15 %
Year on Year Revenue Growth Overall Ranking # 2025
Seqeuential Revenue Change (TTM) 0.97 %
Seq. Revenue Growth (TTM) Overall Ranking # 2025


Cumulative Revenue growth Comment
Assuming the Henry Schein Inc 's fiscal year would have ended in Sep 26 2026, Henry Schein Inc would have reprted above average annual Revenue improvement of 6.15% year on year, of $ 13,734 millions.
This marks a slow-down of the companys growth trends and from the 6.49% growth in Jun 27 2026.

In the Healthcare sector 325 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2025, from total ranking in previous quarter at 2487.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 326
Overall # 2257

Revenue TTM Y/Y Growth Statistics
High Average Low
28.06 %
 4.7 %
-24.36 %
(Jun 26 2021)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 131
Sector # 359
S&P 500 # 2521
Cumulative Revenue growth Comment
Assuming the Henry Schein Inc 's fiscal year would have ended in Sep 26 2026, Henry Schein Inc would have reprted above average annual Revenue improvement of 6.15% year on year, of $ 13,734 millions.
This marks a slow-down of the companys growth trends and from the 6.49% growth in Jun 27 2026.

In the Healthcare sector 325 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2025, from total ranking in previous quarter at 2487.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 121
Healthcare Sector # 326
Overall # 2257

Revenue TTM Y/Y Growth Statistics
High Average Low
28.06 %
4.7 %
-24.36 %
(Jun 26 2021)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 131
Sector # 359
S&P 500 # 2521




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
HSIC's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 26 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 26 2026
Labcorp Holdings Inc 6.92%$ 6.917 millions
Gilead Sciences Inc 6.83%$ 6.835 millions
Arcturus Therapeutics Holdings Inc 6.68%$ 6.682 millions
National Healthcare Corp6.61%$ 6.614 millions
Tenet Healthcare Corp6.47%$ 6.466 millions
Phibro Animal Health Corporation6.32%$ 6.320 millions
Mettler toledo International Inc 6.27%$ 6.273 millions
Agilon Health Inc 5.86%$ 5.864 millions
Johnson and Johnson5.86%$ 5.860 millions
Stoke Therapeutics Inc 5.86%$ 5.860 millions
Genedx Holdings Corp 5.64%$ 5.642 millions
Adma Biologics Inc 5.59%$ 5.595 millions
Innoviva Inc 5.55%$ 5.551 millions
Universal Health Services Inc 5.30%$ 5.297 millions
Acadia Healthcare Company Inc 5.14%$ 5.136 millions
Lumexa Imaging Holdings Inc 5.03%$ 5.032 millions
Bio techne Corp4.75%$ 4.753 millions
Merck and Co Inc 4.68%$ 4.683 millions
Davita Inc 4.62%$ 4.617 millions
Sotera Health Company4.61%$ 4.613 millions
Avantor Inc 4.59%$ 4.588 millions
Icu Medical Inc4.39%$ 4.388 millions
Illumina Inc 4.15%$ 4.151 millions
Agenus Inc4.14%$ 4.144 millions
United Therapeutics Corporation4.13%$ 4.128 millions
Option Care Health Inc 4.09%$ 4.086 millions
Henry Schein Inc 3.95%$ 3.953 millions
Grail Inc 3.71%$ 3.705 millions
Docgo Inc 3.70%$ 3.702 millions
Hca Healthcare Inc 3.59%$ 3.591 millions


About Henry Schein Inc Revenue Growth Rates (HSIC), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Henry Schein Inc (CIK 1000228).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001000228-26-000062
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Henry Schein Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.